Skip to main content
. 2025 Mar 7;20:109. doi: 10.1186/s13023-025-03620-8

Table 2.

Description of the patient reported outcome measurements (PROMs) describing the severity of epistaxis (ESS and NOSE-HHT), anxiety (HADS-A), depression (HADS-D), fatigue (PROMIS-Fatigue-8a), and physical and mental functioning (SF-36) of the study population

Patient population Total (%)
ESS, mean (SD) 5 (2.1)
Mild (1–4) 188 (33)
Moderate (4–7) 266 (47)
Severe (7–10) 111 (20)
NOSE-HHT, mean (SD) 1.7 (0.8)
Mild (0–1) 126 (22)
Moderate (1.01-2) 239 (42)
Severe (> 2) 200 (36)
HADS-D, mean (SD) 6.3 (4)
Normal (0–7) 369 (65)
Borderline abnormal (8–10) 107 (19)
Abnormal (11–21) 89 (16)
HADS-A, mean (SD) 8 (4.3)
Normal (0–7) 275 (49)
Borderline abnormal (8–10) 128 (22)
Abnormal (11–21) 162(22)
PROMIS-Fatigue 8a, mean (SD) 60 (8.5)
Normal limits (20–54) 159 (28)
Mild (55–60) 106 (19)
Moderate (61–70) 242 (43)
Severe (71–80) 58 (10)
SF-36 mean (SD)
General Health 44.3 (22)
Physical Function 60.5 (29)
Physical Limitations 40.8 (41.8)
Emotional Limitations 50.6 (43.7)
Energy 35 (20.7)
Emotional 62.3 (20)
Social 58 (31)
Pain 64 (27)

AVM, arteriovenous malformation; CI, confidence interval; ESS, Epistaxis Severity Score; GI, gastrointestinal; HADS-A, Hospital Anxiety and Depression Scale (Anxiety); HADS-D: Hospital Anxiety and Depression Scale (Depression); NOSE-HHT, Nasal Outcome Score for Epistaxis in Hereditary Hemorrhagic Telangiectasia; PROMIS-Fatigue 8a, Patient-Reported Outcomes Measurement Information System Short Form 8a - Fatigue interfere scale, SD, standard deviation; SE, standard error; SF-36, Short Form-36